Dr. Alpdogan

S. Onder Alpdogan, MD

Contact Dr. Alpdogan

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Relapsed Multiple Myeloma Presenting as Intracranial Plasmacytoma and Malignant Pericardial Effusion following Recent Allogeneic Stem Cell Transplantation
  2. Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization
  3. New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity
  4. Amlodipine-induced hypersensitivity reaction mimicking CD30+ mycosis fungoides
  5. Bullous leukemia cutis in a patient with T-cell prolymphocytic leukemia
  6. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation
  7. A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease
  8. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma
  9. Kaposi sarcoma mimicking multiple cherry angiomata clinically and histologically in a patient with sezary syndrome: An unusual presentation
  10. Advances in immune regulation in transplantation
  11. Interleukin-15 administration increases graft-versus-tumor activity in recipients of haploidentical hematopoietic SCT
  12. Haploidentical hematopoietic SCT increases graft-versus-tumor effect against renal cell carcinoma
  13. Recent advances in haploidentical stem cell transplantation
  14. Immune tolerance and transplantation
  15. Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host or Graft-versus-Graft Effects
  16. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation
  17. Absence of P-selectin in recipients of allogeneic bone marrow transplantation ameliorates experimental graft-versus-host disease
  18. Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation
  19. STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease
  20. Rapidly proliferating CD44hi peripheral T cells undergo apoptosis and delay posttransplantation T-cell reconstitution after allogeneic bone marrow transplantation